Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
May 31, 2019 Off

Axial Biotherapeutics Announces Publication of Preclinical Data Highlighting the Link Between Human Gut Microbiota and Behavioral Symptoms of Autism Spectrum Disorder in Mouse Models

By BusinessWire

WALTHAM, Mass.–(BUSINESS WIRE)–Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and…

May 31, 2019 Off

Generation Bio to Present at Jefferies 2019 Healthcare Conference

By BusinessWire

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Generation Bio, a company developing the first genetic medicines that can be re-dosed and titrated to effect for…

May 31, 2019 Off

Goldfinch Bio to Present at Upcoming Investor Conferences in June

By BusinessWire

CAMBRIDGE, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/conference?src=hash" target="_blank"gt;#conferencelt;/agt;–Goldfinch Bio, Inc., a biotechnology company focused on developing precision therapies for patients with kidney diseases,…

May 31, 2019 Off

NantKwest, NantCell and NantOmics to Provide Updated Preclinical and Clinical Data in Four Abstracts at Part of the American Society of Clinical Oncology Annual Meeting

By BusinessWire

Preclinical and Clinical Data Demonstrate Advanced Deployment of Precision Medicine Tools to Analyze and Potentially More Effectively Intervene with Highly…

May 31, 2019 Off

Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial

By BusinessWire

Survival Benefit Now Observed with KEYTRUDA in Combination with Chemotherapy in All Patient Populations (Regardless of PD-L1 Expression) and with…

May 31, 2019 Off

Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial

By BusinessWire

Survival Benefit Now Observed with KEYTRUDA in Combination with Chemotherapy in All Patient Populations (Regardless of PD-L1 Expression) and with…

May 31, 2019 Off

SFA Therapeutics to Present Human Psoriasis Data for Microbiome-based Drug (SFA002) at the Global Biotech Entrepreneur Forum and the BIO International Convention

By BusinessWire

Also Presenting Preclinical Data on Two Additional Pipeline Products PHILADELPHIA–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/AML?src=hash" target="_blank"gt;#AMLlt;/agt;–SFA Therapeutics, Inc. will be presenting human Psoriasis…

May 31, 2019 Off

Jalyn – API Insight, 2019 – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Jalyn – API Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. Jalyn – API Insight, 2019…

May 31, 2019 Off

Jalyn – API Insight, 2019 – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Jalyn – API Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. Jalyn – API Insight, 2019…

May 31, 2019 Off

Mucosta – API Insight, 2019 – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Mucosta – API Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. Mucosta – API Insight, 2019…

Posts pagination

Previous 1 … 3,147 3,148 3,149 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine